FDA approves Skyrizi (Risankizumab-rzaa) for treatment of moderate or severe plaque psoriasis

psoriasis is a common immune-related chronic inflammatory systemic diseaseAt present, China has more than 6.5 million psoriasis patients, about 30% of the disease has developed to moderate to severe, the quality of life has been greatly affected, and with serious psychological and social burden, nearly half of the unemployment due to illness, some will even choose suicideThe U.Sfda(http://recently approvednew drug(http://,, to treat moderate or severe plaque-type psoriasisThe recommended dose for Skyrizi is 150 mg, with two subcutaneous injections every 12 weeks after the start of treatment and after two initial doses in week 4More conveniently, Skyrizi can inject itself after trainingAbout Skyrizi
Skyrizi is an organ interleukin-23 (IL-23) inhibitorIL-23 is a cytokine involved in the inflammatory process and is thought to be associated with many chronic immunomediated diseases, including psoriasisSkyrizi's approval is based on the clinical trial (http:// (ultIMMa-1, ultIMMa-2, IMMhance, IMMvent) in four Phase 3 psoriasis projects In clinical trials, Skyrizi has a high rate of persistent skin disease removal The vast majority of people treated with Skyrizi (82% and 81%) achieved a 90% skin disease removal rate within a year, and some (56% and 60%) achieved a complete skin disease removal rate 　　In terms of safety
the most common adverse events in Skyrizi included upper respiratory tract infections (13%), headache (3.5%), fatigue (2.5%), injection site reactions (1.5%) and infections (1.1%) 　　Currently, Skyrizi has been approved in the United States for use in adults with severe plaque-type psoriasis for systemic therapy or phototherapy, and in Japan approved for the treatment of plaque-type psoriasis, generalized pustules psoriasis, red-skin psoriasis, and psoriasis arthritis in adult psoriasis patients with inadequate response